journal article·2016-09-14

Nanostructured Antagonist of Extrasynaptic NMDA Receptors

Alex Savchenko, Gary B. Braun, Elena Molokanova

Nano Letters· Volume 16· Issue 9
Publisher page

Abstract

Glutamatergic cytotoxicity mediated by overactivation of N-methyl-d-aspartate receptors (NMDARs) is implicated in numerous neurological disorders. To be therapeutically viable, NMDAR antagonists must preserve physiological role of synaptic NMDARs (sNMDARs) in synaptic transmission and block only excessive pathological activation of NMDARs. Here we present a novel NMDAR antagonist that satisfies this two-fold requirement by exploiting spatial differences in NMDAR subcellular locations. Specifically, we designed a hybrid nanodrug (AuM) to be larger than the synaptic cleft by attaching memantine, NMDAR antagonist, via polymer linkers to a gold nanoparticle. We show that AuM efficiently and selectively inhibited extrasynaptic NMDARs (eNMDARs), while having no effect on sNMDARs and synaptic transmission. AuM exhibited neuroprotective properties both in vitro and ex vivo during such neurotoxic insults as NMDAR-mediated cytotoxicity in cerebrocortical cell culture and oxygen-glucose deprivation in acute hippocampal slices. Furthermore, AuM prevented dendritic spine loss triggered by Aβ oligomers in organotypic hippocampal slices and was more effective than free memantine. Using a novel rational design strategy, we demonstrate a proof of concept for a new class of neuroprotective drugs that might be beneficial for treatment of several neurological disorders.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Neuroscience and Neuropharmacology Research · Molecular Sensors and Ion Detection · Neuroscience and Neural Engineering

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Bioengineering and Pediatrics, University of California, San Diego, California 92093, United States

Stanford University, Stanford, California 94305, United States

Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States

Nanotools Bioscience, Encinitas, California 92024, United States

Funding

National Institutes of Health

References (48)

Show source-provided references
1. 10.1016/0896-6273(88)90162-610.1016/0896-6273(88)90162-6 ↗
2. 10.1016/S1474-4422(08)70165-010.1016/S1474-4422(08)70165-0 ↗
3. 10.1016/S1474-4422(02)00164-310.1016/S1474-4422(02)00164-3 ↗
4. 10.1038/nrn222910.1038/nrn2229 ↗
5. 10.1038/nrn291110.1038/nrn2911 ↗
6. 10.1038/nn207110.1038/nn2071 ↗
7. 10.1038/nn83510.1038/nn835 ↗
8. 10.1016/j.neuron.2007.01.02510.1016/j.neuron.2007.01.025 ↗
9. 10.1038/nm.205610.1038/nm.2056 ↗
10. 10.1073/pnas.130683211010.1073/pnas.1306832110 ↗
11. 10.1016/j.neuron.2014.03.03010.1016/j.neuron.2014.03.030 ↗
12. 10.1016/S0896-6273(02)00658-X10.1016/S0896-6273(02)00658-X ↗
13. 10.1016/j.neuroscience.2010.01.02210.1016/j.neuroscience.2010.01.022 ↗
14. 10.1038/nrn350410.1038/nrn3504 ↗
15. 10.1111/j.1476-5381.2012.02057.x10.1111/j.1476-5381.2012.02057.x ↗
16. Chen H. · J. Neurosci. · 1992 · 12 · 442710.1523/JNEUROSCI.12-11-04427.1992 ↗
17. 10.1113/jphysiol.1997.sp02190910.1113/jphysiol.1997.sp021909 ↗
18. 10.1016/j.coph.2005.09.00710.1016/j.coph.2005.09.007 ↗
19. 10.1523/JNEUROSCI.2488-10.201010.1523/JNEUROSCI.2488-10.2010 ↗
20. Rusakov D. A. · J. Neurosci. · 1998 · 18 · 315810.1523/JNEUROSCI.18-09-03158.1998 ↗
21. 10.1039/c3ra22739a10.1039/c3ra22739a ↗
22. 10.1039/c2cs15260f10.1039/c2cs15260f ↗
23. 10.1021/nl900031y10.1021/nl900031y ↗
24. 10.1021/ja907128210.1021/ja9071282 ↗
25. 10.1021/la900545t10.1021/la900545t ↗
26. 10.2217/nnm.11.1910.2217/nnm.11.19 ↗
27. Lester, R.; Clements, J. D.; Tong, G.; Westbrook, G. L.; Jahr, C. E.The time course of NMDA receptor-mediated synaptic currents. InThe NMDA receptor;Collingridge, G. L.; Watkins, J. C., Eds.Oxford:New York, 1994; Vol.11, pp206–218.10.1093/acprof:oso/9780192625021.003.0008 ↗
28. 10.1146/annurev.ph.57.030195.00243110.1146/annurev.ph.57.030195.002431 ↗
29. 10.1021/jm300945810.1021/jm3009458 ↗
30. 10.1113/jphysiol.2009.17629710.1113/jphysiol.2009.176297 ↗
31. Cottrell J. R. · J. Neurophysiol. · 2000 · 84 · 157310.1152/jn.2000.84.3.1573 ↗
32. 10.1073/pnas.050942510310.1073/pnas.0509425103 ↗
33. 10.1126/scitranslmed.300359410.1126/scitranslmed.3003594 ↗
34. 10.1523/JNEUROSCI.6371-11.201210.1523/JNEUROSCI.6371-11.2012 ↗
35. 10.1016/j.neuropharm.2013.01.02410.1016/j.neuropharm.2013.01.024 ↗
36. 10.1038/nn.258310.1038/nn.2583 ↗
37. 10.1523/JNEUROSCI.4970-06.200710.1523/JNEUROSCI.4970-06.2007 ↗
38. 10.1038/nm178210.1038/nm1782 ↗
39. 10.1155/2012/31983610.1155/2012/319836 ↗
40. 10.1038/nn.247610.1038/nn.2476 ↗
41. 10.1073/pnas.060094810310.1073/pnas.0600948103 ↗
42. 10.1016/j.mcn.2006.07.01110.1016/j.mcn.2006.07.011 ↗
43. 10.1073/pnas.090870610610.1073/pnas.0908706106 ↗
44. 10.1523/JNEUROSCI.0203-11.201110.1523/JNEUROSCI.0203-11.2011 ↗
45. 10.1039/c0nr00345j10.1039/c0nr00345j ↗
46. 10.1016/j.colsurfb.2008.07.00410.1016/j.colsurfb.2008.07.004 ↗
47. 10.1039/C1CC15113D10.1039/C1CC15113D ↗
48. Palmer A. M. · J. Alzheimer’s Dis. · 2011 · 24 · 64310.3233/JAD-2011-110368 ↗